Biological and functional characteristics of a novel low–molecular weight antagonist of glucose‐dependent insulinotropic polypeptide receptor, SKL‐14959, in vitro and in vivo
Authors:
- 22 December 2011
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 14 (6) , 511-517
Abstract
Aim: We recently discovered a glucose‐dependent insulinotropic polypeptide (GIP) receptor antagonist, SKL‐14959. GIP plays a role in the glucose and lipid metabolism, and is associated with obesity and insulin resistance. Therefore, we aimed to ascertain the inhibitory potency and glucose and lipid metabolism of SKL‐14959. Methods: SKL‐14959 was evaluated for its binding affinity to each GIP, glucagon‐like peptide‐1 (GLP‐1) and glucagon receptors by each labelled and non‐labelled ligand; GIP‐stimulated cyclic AMP (cAMP) production in CHO cells expressing human GIP receptor in vitro . Oral and intraperitoneal glucose tolerance tests (OGTT and IPGTT) were performed to examine the insulinotropic effect on endogenous and exogenous GIP. Oil tolerance tests were also conducted to examine the lipid metabolism and the postheparin plasma lipase activity, lipoprotein lipase (LPL) and hepatic lipase (HL). Result: SKL‐14959 selectively bound to GIP receptor and inhibited GIP‐stimulated cAMP production with the Ki value of 55 nM and an IC 50 value of 2.9 µM, respectively. SKL‐14959·Na significantly increased blood glucose levels, inhibited insulin secretion in OGTT and inhibited the plasma glucose lowering of exogenous GIP in IPGTT. Furthermore, SKL‐14959 increased plasma triacylglycerol (TG) levels as well as suppressed the postheparin plasma lipase activity in an oil load test. Conclusion: These data indicate that SKL‐14959 is distinguished in the physiological phenotype of GIP following direct binding to the receptor.Keywords
This publication has 46 references indexed in Scilit:
- Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in AdipocytesJournal of Biological Chemistry, 2007
- Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin actionBiochemical and Biophysical Research Communications, 2005
- GIP as a Potential Therapeutic Agent?Hormone and Metabolic Research, 2004
- Characterization of the Cellular and Metabolic Effects of a Novel Enzyme-Resistant Antagonist of Glucose-Dependent Insulinotropic PolypeptideBiochemical and Biophysical Research Communications, 2002
- Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.Journal of Clinical Investigation, 1996
- Effects of Gastric Inhibitory Polypeptide on Glucose and Lipid Metabolism of Isolated Rat AdipocytesAnnals of Nutrition and Metabolism, 1988
- Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.Journal of Clinical Investigation, 1981
- Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intoleranceEuropean Journal of Clinical Investigation, 1979
- The incretin concept todayDiabetologia, 1979
- Preparation of highly active enterogastroneCanadian Journal of Physiology and Pharmacology, 1969